See more : GeoVax Labs, Inc. (GOVXW) Income Statement Analysis – Financial Results
Complete financial analysis of Aileron Therapeutics, Inc. (ALRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aileron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Transtech Optelecom Science Holdings Limited (9963.HK) Income Statement Analysis – Financial Results
- Triad Business Bank (TBBC) Income Statement Analysis – Financial Results
- Torrent Pharmaceuticals Limited (TORNTPHARM.NS) Income Statement Analysis – Financial Results
- Bhagiradha Chemicals & Industries Limited (BHAGCHEM.NS) Income Statement Analysis – Financial Results
- Water Ways Technologies Inc. (WWTIF) Income Statement Analysis – Financial Results
Aileron Therapeutics, Inc. (ALRN)
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.35M |
| Cost of Revenue | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 9.33M | 12.23M |
| Gross Profit | -119.00K | -169.00K | -121.00K | -163.00K | -155.00K | -218.00K | -95.00K | -232.00K | -325.00K | -9.33M | 10.12M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45.29% |
| Research & Development | 3.99M | 17.97M | 17.01M | 11.17M | 17.66M | 18.45M | 14.24M | 10.28M | 7.83M | 9.33M | 12.23M |
| General & Administrative | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Other Expenses | 928.00K | 318.00K | 441.00K | -800.00K | 0.00 | 0.00 | 0.00 | -18.17M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 6.70M | 6.84M |
| Cost & Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 16.03M | 19.07M |
| Interest Income | 0.00 | 0.00 | 0.00 | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 585.00K | 774.00K |
| EBITDA | -15.61M | -27.48M | -26.48M | -20.33M | -29.80M | -31.33M | -23.01M | -17.94M | -12.57M | -15.44M | 4.06M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 18.16% |
| Operating Income | -16.28M | -27.65M | -26.61M | -20.50M | -29.96M | -31.90M | -23.01M | -18.17M | -12.89M | -16.03M | 3.28M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.69% |
| Total Other Income/Expenses | 544.00K | 318.00K | 441.00K | -661.00K | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K |
| Income Before Tax | -15.73M | -27.33M | -26.21M | -21.16M | -29.37M | -31.55M | -22.60M | -18.12M | -12.88M | -16.02M | 3.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.72% |
| Income Tax Expense | 0.00 | -318.00K | -441.00K | 661.00K | -587.00K | 355.00K | 34.00K | 0.00 | 0.00 | 43.00K | 3.10M |
| Net Income | -15.73M | -27.01M | -25.76M | -21.82M | -28.78M | -31.55M | -22.60M | -18.12M | -12.88M | -16.07M | 194.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.87% |
| EPS | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -845.63 | 10.21 |
| EPS Diluted | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -844.96 | 10.85 |
| Weighted Avg Shares Out | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.00K | 19.00K |
| Weighted Avg Shares Out (Dil) | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.02K | 17.89K |
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent effects in five biomarkers evaluated compared to low dose LTI-03 Data...
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic...
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Agreement marks first of its kind for Advancium, a public charity launched by Deerfield Management and the Deerfield Foundation Advancium will evaluate ALRN-6924 as a potential therapy for retinoblastoma, a rare but devastating pediatric cancer of the eye AUSTIN, Texas and...
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers evaluated, suggesting potential therapeutic effect Recently...
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Cohort 2 will evaluate high-dose LTI-03 (5 mg BID) Previously announced Cohort 1 data demonstrated positive trends in seven of the eight biomarkers evaluated, suggesting a potential therapeutic effect AUSTIN, Texas , Sept. 23, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc....
Aileron Therapeutics to Present at the 8th Annual IPF Summit
AUSTIN, Texas , Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian...
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in idiopathic pulmonary fibrosis ("IPF") patients, with positive trends observed in seven of the eight biomarkers evaluated Topline...
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
AUSTIN, Texas , July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian...
Aileron Therapeutics to be Included in the Russell Microcap® Index
AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced...
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated
Source: https://incomestatements.info
Category: Stock Reports